

# Pyrenosetins A–C, New Decalinoylspirotetramic Acid Derivatives Isolated by Bioactivity-Based Molecular Networking from the Seaweed-Derived Fungus *Pyrenochaetopsis* sp. FVE-001

Bicheng Fan <sup>1</sup>, Pradeep Dewapriya <sup>1</sup>, Fengjie Li <sup>1</sup>, Martina Blümel <sup>1</sup> and Deniz Tasdemir <sup>1,2,\*</sup>

<sup>1</sup> GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Research Unit Marine Natural Products Chemistry, GEOMAR Helmholtz Centre for Ocean Research Kiel, Am Kiel-Kanal 44, 24106 Kiel, Germany; bfan@geomar.de (B.F.); pdewapriya@geomar.de (P.D.); fli@geomar.de (F.L.); mbluemel@geomar.de (M.B.)

<sup>2</sup> Faculty of Mathematics and Natural Sciences, Kiel University, Christian-Albrechts-Platz 4, 24118 Kiel, Germany

\* Correspondence: dtasdemir@geomar.de; Tel.: +49-431-600-4430

## List of Tables

**Table S1.** In vitro anticancer activity (%) of Kupchan subextracts (KH, KC, KM) and SPE fractions against cancer cell lines (A-375, A-549, HT-29, HCT-116, MB-231) and non-cancerous HaCaT cell line.

**Table S2.** The  $\Delta\delta(\delta_S-\delta_R)$  data for the *S*- and *R*-MTPA esters **6-9** in <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz).

**Table S3.** The distance (Å) between protons H-5', H-15 and H<sub>3</sub>-17 in the tetramic acid portion of the compounds **1-3**. The red marking indicates the assigned relative stereochemistry based on the measured distances allowing observable NOE correlations (up to 4 Å) between relevant protons.

## List of Figures

**Figure S1.** <sup>1</sup>H NMR spectrum of compound **1** (600 MHz, CDCl<sub>3</sub>).

**Figure S2.** <sup>13</sup>C NMR spectrum of compound **1** (150 MHz, CDCl<sub>3</sub>).

**Figure S3.** DEPT-HSQC spectrum of compound **1** (600 MHz, CDCl<sub>3</sub>).

**Figure S4.** COSY spectrum of compound **1** (600 MHz, CDCl<sub>3</sub>).

**Figure S5.** HMBC spectrum of compound **1** (600 MHz, CDCl<sub>3</sub>).

**Figure S6.** NOESY spectrum of compound **1** (600 MHz, CDCl<sub>3</sub>).

**Figure S7.** HR-ESIMS spectrum of compound **1**.

**Figure S8.** FT-IR spectrum of compound **1**.

**Figure S9.** <sup>1</sup>H NMR spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).

**Figure S10.** <sup>13</sup>C NMR spectrum of compound **2** (150 MHz, CDCl<sub>3</sub>).

**Figure S11.** DEPT-HSQC spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).

**Figure S12.** COSY spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).

**Figure S13.** HMBC spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).

**Figure S14.** NOESY spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).

**Figure S15.** HR-ESIMS spectrum of compound **2**.

**Figure S16.** FT-IR spectrum of compound **2**.

**Figure S17.** <sup>1</sup>H NMR spectrum of compound **3** (600 MHz, CDCl<sub>3</sub>).

**Figure S18.** <sup>13</sup>C NMR spectrum of compound **3** (150 MHz, CDCl<sub>3</sub>).

**Figure S19.** DEPT-HSQC spectrum of compound **3** (600 MHz, CDCl<sub>3</sub>).

**Figure S20.** COSY spectrum of compound **3** (600 MHz, CDCl<sub>3</sub>).

**Figure S21.** HMBC spectrum of compound **3** (600 MHz, CDCl<sub>3</sub>).

**Figure S22.** NOESY spectrum of compound **3** (600 MHz, CDCl<sub>3</sub>).

**Figure S23.** HR-ESIMS spectrum of compound **3**.

**Figure S24.** FT-IR spectrum of compound **3**.

**Figure S25.** <sup>1</sup>H NMR spectrum of 16-(*S*)-MTPA ester **6** (500 MHz, CDCl<sub>3</sub>).

**Figure S26.** <sup>1</sup>H NMR spectrum of 16-(*R*)-MTPA ester **7** (500 MHz, CDCl<sub>3</sub>).

**Figure S27.** <sup>1</sup>H NMR spectrum of 16-(*S*)-MTPA ester **8** (500 MHz, CDCl<sub>3</sub>).

**Figure S28.** <sup>1</sup>H NMR spectrum of 16-(*R*)-MTPA ester **9** (500 MHz, CDCl<sub>3</sub>).

**Figure S29.**  $\Delta\delta(\delta_S-\delta_R)$  values (ppm) obtained from 16-MTPA esters (**6** and **7**) of compound **1**.

**Figure S30.**  $\Delta\delta(\delta_S-\delta_R)$  values (ppm) obtained from 16-MTPA esters (**8** and **9**) of compound **2**.

**Table S1.** In vitro anticancer activity (%) of Kupchan subextracts (KH, KC, KM) and SPE fractions against cancer cell lines (A-375, A-549, HT-29, HCT-116, MB-231) and non-cancerous HaCaT cell line.

Cell growth inhibition (%)						
	A-375 (100 µg/ml)	A-549 (100 µg/ml)	HT-29 (100 µg/ml)	HCT-116 (100 µg/ml)	MB-231 (100 µg/ml)	HaCaT (100 µg/ml)
KH	31	0	29	0	0	31
KC	98	99	99	76	99	66
KM	0	0	0	0	0	0
KC Fr.0	0	0	0	0	0	0
KC Fr.1	0	0	0	0	0	0
KC Fr.2	0	0	0	0	0	0
KC Fr.3	0	0	0	0	0	0
KC Fr.4	0	0	0	0	0	0
KC Fr.5	85	54	99	0	63	44
KC Fr.6	99	99	99	99	99	99
KC Fr.7	99	99	99	99	99	99
KC Fr.8	43	0	0	0	0	0
KC Fr.9	0	0	0	0	0	0
KC Fr.10	0	0	0	0	0	0

**Table S2.** The  $\Delta\delta(\delta_S-\delta_R)$  data for the *S*- and *R*-MTPA esters **6–9** in  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz).

	<b>6 (S)</b>	<b>7 (R)</b>	$\Delta\delta_{S-R}$	<b>8 (S)</b>	<b>9 (R)</b>	$\Delta\delta_{S-R}$
<b>C</b>	$\delta_H$ , mult ( <i>J</i> in Hz)	$\delta_H$ , mult ( <i>J</i> in Hz)		$\delta_H$ , mult ( <i>J</i> in Hz)	$\delta_H$ , mult ( <i>J</i> in Hz)	
13	3.39, m	3.35, dd (11.5, 9.5)	0.04	3.27, dd (11.3, 9.7)	3.28, dd (11.4, 9.4)	-0.01
14	5.92, dd (15.5, 9.5)	5.84, dd (15.4, 9.8)	0.08	6.09, dd (14.8, 9.7)	6.10, dd (15.3, 9.7)	-0.01
15	5.65, dd (15.5, 6.4)	5.58, dd (15.4, 6.4)	0.07	5.39, dd (14.9, 7.8)	5.52, dd (15.3, 7.6)	-0.13
16	5.46, m	5.45, m	0.01	5.34, m	5.38, m	-0.04
17	1.22, d (6.5)	1.30, d (6.5)	-0.08	1.31, d (6.3)	1.27, d (6.5)	0.04

**Table S3.** The distance (Å) between protons H-5', H-15 and H<sub>3</sub>-17 in the tetramic acid portion of the compounds 1-3. The red marking indicates the assigned relative stereochemistry based on measured the distances allowing observable NOE correlations (up to 4 Å) between relevant protons.













Compd	2D Structure	3D model	H-5' orientation	Distance	NOE	Distance	NOE
				H-5'/H-15	H-5'/H-15	H-5'/H <sub>3</sub> -17	H-5'/H <sub>3</sub> -17
1 (5'-β)			β	2.96 Å	YES	3.28 Å	YES
1 (5'-α)			α	4.83 Å		5.07 Å	
2 (5'-β)			β	2.88 Å		3.33 Å	
2 (5'-α)			α	5.14 Å	NO	6.84 Å	NO
3 (5'-β)			β	3.80 Å		5.11 Å	
3 (5'-α)			α	5.41 Å	NO	6.77 Å	NO

Figure S1.  $^1\text{H}$  NMR spectrum of compound **1** (600 MHz,  $\text{CDCl}_3$ ).




Figure S2.  $^{13}\text{C}$  NMR spectrum of compound **1** (150 MHz,  $\text{CDCl}_3$ ).




Figure S3. DEPT-HSQC spectrum of compound 1 (600 MHz, CDCl<sub>3</sub>).




Figure S4. COSY spectrum of compound 1 (600 MHz, CDCl<sub>3</sub>).




Figure S5. HMBC spectrum of compound 1 (600 MHz, CDCl<sub>3</sub>).




Figure S6. NOESY spectrum of compound 1 (600 MHz, CDCl<sub>3</sub>).




Figure S7. HR-ESIMS spectrum of compound 1.




Figure S8. FT-IR spectrum of compound 1.








Figure S11. DEPT-HSQC spectrum of compound 2 (600 MHz, CDCl<sub>3</sub>).




Figure S12. COSY spectrum of compound 2 (600 MHz, CDCl<sub>3</sub>).




Figure S13. HMBC spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).




Figure S14. NOESY spectrum of compound **2** (600 MHz, CDCl<sub>3</sub>).




Figure S15. HR-ESIMS spectrum of compound 2.




Figure S16. FT-IR spectrum of compound 2.




Figure S17.  $^1\text{H}$  NMR spectrum of compound 3 (600 MHz,  $\text{CDCl}_3$ ).




Figure S18.  $^{13}\text{C}$  NMR spectrum of compound 3 (150 MHz,  $\text{CDCl}_3$ ).




Figure S19. DEPT-HSQC spectrum of compound 3 (600 MHz, CDCl<sub>3</sub>).




Figure S20. COSY spectrum of compound 3 (600 MHz, CDCl<sub>3</sub>).




Figure S21. HMBC spectrum of compound 3 (600 MHz, CDCl<sub>3</sub>).




Figure S22. NOESY spectrum of compound 3 (600 MHz, CDCl<sub>3</sub>).




Figure S23. HR-ESIMS spectrum of compound 3.




Figure S24. FT-IR spectrum of compound 3.






Figure S25.  $^1\text{H}$  NMR spectrum of 16-(*S*)-MTPA ester **6** (500 MHz,  $\text{CDCl}_3$ ).




Figure S26.  $^1\text{H}$  NMR spectrum of 16-(*R*)-MTPA ester **7** (500 MHz,  $\text{CDCl}_3$ ).




Figure S27. <sup>1</sup>H NMR spectrum of 16-(S)-MTPA ester **8** (500 MHz, CDCl<sub>3</sub>).






Figure S28. <sup>1</sup>H NMR spectrum of 16-(R)-MTPA ester **9** (500 MHz, CDCl<sub>3</sub>).



**Figure S29.**  $\Delta\delta(\delta_S-\delta_R)$  values (ppm) obtained from 16-MTPA esters (6 and 7) of compound 1.



**Figure S30.**  $\Delta\delta(\delta_S-\delta_R)$  values (ppm) obtained from 16-MTPA esters (8 and 9) of compound 2.

